Want to see VVOS full AI Analyst Report?
VVOS Stock Chart & Stats
$2.22
-$0.06(-1.47%)
At close: 4:00 PM EST
$2.22
-$0.06(-1.47%)
Day’s Range― - ―
52-Week Range$0.38 - $7.40
Previous CloseN/A
Volume144.69K
Average Volume (3M)421.86K
Market Cap
$6.00M
Enterprise Value$13.17M
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 19, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.30
Shares Outstanding13,894,600
10 Day Avg. Volume324,525
30 Day Avg. Volume421,860
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)-14.00
Price to Sales (P/S)1.20
P/FCF Ratio-1.18
Enterprise Value/Market Cap2.19
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.56
Forecast
1Y Price Target
$2.12Price Target Upside-4.65% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.41
Revenue Forecast (FY)$23.25M
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Patient Volume GrowthSustained double-digit top-line growth and a large rise in completed patient appointments indicate durable demand for Vivos' non‑surgical OSA model. Higher patient throughput creates a repeatable revenue base and provides a path to scale provider networks and per‑provider productivity over months.
High And Improving Gross MarginsA ~60% gross margin shows strong product and service unit economics, implying the core offering can generate healthy contribution as volumes grow. Durable margin strength from higher‑margin diagnostics and service revenue supports eventual operating leverage if SG&A growth is controlled.
Strategic Clinical Expansion And Vertical IntegrationAcquisitions and physician‑aligned ventures expand referral pathways and diversify revenue beyond device sales into diagnostics, clinic services and medical affiliations. Vertical integration into sleep centers and specialty referrals can sustainably increase patient flow and contribution margins.
Bears Say
Stressed Balance Sheet And Negative EquityNegative equity and material debt materially reduce financial flexibility, increasing refinancing and dilution risk. This structural capital weakness constrains investment in growth initiatives, limits runway for margin programs, and risks listing compliance until remedied.
Persistent Cash Burn And Weak Cash GenerationSustained negative operating and free cash flow necessitates ongoing external financings, raising the probability of dilutive or costly capital. Chronic cash burn limits ability to fund expansions, delays margin realization, and forces near‑term prioritization of liquidity over strategic investments.
Rising G&A And Integration Execution RiskA large G&A increase tied to acquisitions and integration costs erodes operating leverage and can outpace revenue gains if not controlled. Execution risk from integrating SCN and scaling provider networks may keep costs elevated and impede delivery of forecasted practice‑level margins.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $0.38 and its highest was $7.40 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $6.00M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 36 days.
How were Vivos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.39.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 13,894,600 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
VVOS Stock 12 Month Forecast
Average Price Target
$2.12
▼(-4.65% Downside)
Technical Analysis
Iridex
―
Co-Diagnostics
―
Adagio Medical Holdings
―
Envoy Medical
―
Nexalin Technology, Inc.
―
Ownership Overview
9.74% Insiders
2.26% Mutual Funds
0.26% Other Institutional Investors
85.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---